Candriam S.C.A. Y M Abs Therapeutics, Inc. Transaction History

Candriam S.C.A.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$6.55 - $17.42 $72,757 - $193,501	-11,108 Reduced 6.05%	172,584 $2.05 Million
Q4 2021 Feb 10, 2022	BUY	$15.51 - $29.31 $85,475 - $161,527	5,511 Added 3.09%	183,692 $2.98 Million
Q3 2021 Nov 09, 2021	SELL	$27.47 - $37.31 $82,410 - $111,930	-3,000 Reduced 1.66%	178,181 $5.09 Million
Q2 2021 Jul 20, 2021	BUY	$25.45 - $37.64 $31,456 - $46,523	1,236 Added 0.69%	181,181 $9.26 Million
Q1 2021 Apr 29, 2021	SELL	$29.16 - $51.96 $29 - $51	-1 Reduced -0.0%	179,945 $8.56 Million
Q4 2020 Jan 22, 2021	SELL	$37.86 - $54.26 $104,417 - $149,649	-2,758 Reduced 1.51%	179,946 $8.91 Million
Q3 2020 Oct 19, 2020	BUY	$35.13 - $43.62 $622,046 - $772,379	17,707 Added 10.73%	182,704 $7.01 Million
Q2 2020 Jul 23, 2020	BUY	$23.66 - $49.53 $2.54 Million - $5.32 Million	107,451 Added 186.72%	164,997 $7.13 Million
Q1 2020 May 26, 2020	BUY	$14.39 - $35.8 $287 - $716	20 Added 0.03%	57,546 $1.76 Million
Q4 2019 Jan 21, 2020	BUY	$23.81 - $33.78 $1.37 Million - $1.94 Million	57,526 New	57,526 $2,000

106

24.5M

40.3K

400

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $487M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.